`
`UNITED STATES DISTRICT COURT
`for the
`Northern District of West Virginia
`
`Regeneron Pharmaceuticals, Inc.
`Plaintiff(s)
` v.
`Mylan Pharmaceuticals, Inc., et al.
`Defendant(s)
`
`Civil Action No. 1:22-cv-61
`
`JUDGMENT IN A CIVIL ACTION
`
`The court has ordered that:
`Judgment award
`
`Judgment costs
`
`Other
`
`other:
`
`The Court concludes that Regeneron has demonstrated by a preponderance of the evidence that the
`Defendants have infringed claims 4, 7, 9, 11, 14, 15, 16, and 17 of the ’865 Patent; Regeneron has
`demonstrated by a preponderance of the evidence that the Defendants will induce infringement of claims 6
`and 25 of the ’572 Patent and claims 11 and 19 of the ’601 Patent; (continued below)
`
`This action was:
`tried by jury
`
`tried by judge
`
`decided by judge
`
`decided by Judge Thomas S. Kleeh
`Mylan has not demonstrated by clear and convincing evidence that claims 4, 7, 9, 11, 14, 15, 16, and 17 of the ’865 Patent are anticipated or
`obvious in light of the prior art or invalid under 35 U.S.C. § 112 for lack of written description, lack of enablement, or indefiniteness. Mylan
`has not demonstrated by clear and convincing evidence that claim 6 of the ’572 Patent is invalid as anticipated; Mylan has demonstrated by
`clear and convincing evidence that claim 6 of the ’572 Patent is invalid as obvious; Mylan has not demonstrated by clear and convincing
`evidence that claim 25 of the ‘572 patent is invalid as anticipated; Mylan has demonstrated by clear and convincing evidence that claim 25
`of the ‘572 patent is invalid as obvious; Mylan has not demonstrated by clear and convincing evidence that Claim 11 of the ‘601 Patent is
`invalid as anticipated; Mylan has demonstrated by clear and convincing evidence that Claim 11 of the ‘601 patent is invalid as obvious;
`Mylan has demonstrated by clear and convincing evidence that Claim 19 of the ‘601 Patent is invalid as obvious.
`CLERK OF COURT
`Cheryl Dean Riley
`/s/ D. Kinsey
`
`Date: December 27, 2023
`
`Signature of Clerk or Deputy Clerk
`
`